Seven Eight Capital LP bought a new position in shares of MEDNAX Inc (NYSE:MD) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 51,306 shares of the company’s stock, valued at approximately $2,394,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in MD. Oregon Public Employees Retirement Fund increased its stake in MEDNAX by 3.4% during the second quarter. Oregon Public Employees Retirement Fund now owns 36,599 shares of the company’s stock worth $1,584,000 after acquiring an additional 1,196 shares during the last quarter. LPL Financial LLC increased its stake in MEDNAX by 8.9% during the first quarter. LPL Financial LLC now owns 15,153 shares of the company’s stock worth $843,000 after acquiring an additional 1,233 shares during the last quarter. Janus Henderson Group PLC increased its stake in MEDNAX by 0.4% during the second quarter. Janus Henderson Group PLC now owns 316,826 shares of the company’s stock worth $13,714,000 after acquiring an additional 1,300 shares during the last quarter. SG Americas Securities LLC increased its stake in MEDNAX by 8.8% during the second quarter. SG Americas Securities LLC now owns 17,350 shares of the company’s stock worth $751,000 after acquiring an additional 1,398 shares during the last quarter. Finally, GHP Investment Advisors Inc. increased its stake in MEDNAX by 19.8% during the third quarter. GHP Investment Advisors Inc. now owns 9,775 shares of the company’s stock worth $456,000 after acquiring an additional 1,615 shares during the last quarter. Hedge funds and other institutional investors own 95.88% of the company’s stock.

A number of equities research analysts have recently issued reports on the company. Robert W. Baird lowered their target price on MEDNAX from $50.00 to $48.00 and set a “neutral” rating for the company in a research note on Friday. Leerink Swann upgraded MEDNAX from a “market perform” rating to an “outperform” rating in a research note on Monday, September 24th. Bank of America upgraded MEDNAX from an “underperform” rating to a “neutral” rating and lowered their target price for the company from $60.00 to $50.00 in a research note on Tuesday, September 18th. Zacks Investment Research upgraded MEDNAX from a “sell” rating to a “hold” rating in a research note on Tuesday, August 7th. Finally, ValuEngine upgraded MEDNAX from a “strong sell” rating to a “sell” rating in a research note on Friday, August 3rd. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and five have given a buy rating to the company. MEDNAX currently has an average rating of “Hold” and a consensus price target of $54.00.

In related news, insider John C. Pepia sold 3,500 shares of the stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $48.18, for a total value of $168,630.00. Following the completion of the transaction, the insider now owns 30,148 shares of the company’s stock, valued at $1,452,530.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 2.70% of the company’s stock.

MD stock opened at $42.68 on Tuesday. The stock has a market capitalization of $4.04 billion, a PE ratio of 12.55, a P/E/G ratio of 1.19 and a beta of 0.23. MEDNAX Inc has a 1 year low of $40.56 and a 1 year high of $63.04. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.59.

MEDNAX (NYSE:MD) last issued its quarterly earnings results on Thursday, August 2nd. The company reported $1.07 EPS for the quarter, meeting analysts’ consensus estimates of $1.07. The firm had revenue of $915.90 million during the quarter, compared to the consensus estimate of $911.77 million. MEDNAX had a return on equity of 10.42% and a net margin of 9.59%. MEDNAX’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.85 earnings per share. Equities analysts predict that MEDNAX Inc will post 3.64 earnings per share for the current year.

MEDNAX Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

See Also: What are retained earnings?

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.